Abbott's robust strength in Core Diagnostics and EPD businesses should continue to benefit in the upcoming quarters.

Abbott's robust strength in Core Diagnostics and EPD businesses should continue to benefit in the upcoming quarters.

ITW gains from strength in its businesses, enterprise initiatives and shareholder-friendly moves. Softness in semiconductor-related business persists.

CSL benefits from strength across its business, acquisitions and shareholder-friendly policies. Rising costs and expenses may hurt its profitability.

AXON benefits from strength across its businesses, product introductions and complementary acquisitions. Rising costs and expenses may hurt its...

BRKR's robust growth potential across its major segments is encouraging. Yet, macro woes and competitive pressure can pose challenges.

Hologic's business diversification holds strong potential internationally. Also, its discounted valuation makes it attractive from an investment...

Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.

Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.

VIRT is expected to benefit from improved trading income and expanding execution services business.